Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.31 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22047456 | 1.00 | FAAH (0.39) | FAAHMEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL22018660 | 0.85 | FAAH (0.56) | FAAHMEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL22019559 | 0.83 | TSHR (0.42) | FAAHMEN1MAPK1KMT2A | |
| SCHEMBL22019557 | 0.83 | TSHR (0.42) | FAAHMEN1MAPK1KMT2A | |
| SCHEMBL22018460 | 0.83 | PSMB5 (0.43) | FAAHMEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL25052997 | 0.71 | FAAH (0.54) | FAAHMEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL26231705 | 0.71 | FAAH (0.42) | FAAHMEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL26231684 | 0.71 | FAAH (0.42) | FAAHMEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL20436320 | 0.71 | AKT1 (0.36) | FAAHSMN1; SMN2 | |
| SCHEMBL20436175 | 0.71 | AKT1 (0.36) | FAAHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230114-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2021-07-29 | — | — | US | disclosed |
| US-10913713-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200172481-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2020-06-04 | — | — | US | disclosed |
| WO-2020102053-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230114-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRA6 | FAAH 2024/4885MEN1 2163/4885MAPK1 3961/4885 |
| US-10913713-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRA6 | FAAH 2024/4885MEN1 2163/4885MAPK1 3961/4885 |
| US-20200172481-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRA6 | FAAH 2024/4885MEN1 2163/4885MAPK1 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.